Enbrel Phase III Data Shows Significant Improvement In Pediatric Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Enbrel could be the first biologic to treat pediatric patients' chronic moderate to severe plaque psoriasis.
You may also be interested in...
FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis
Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.
FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis
Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.
Enbrel “Black Box” Under Consideration By FDA, Amgen Execs Say
Amgen also has received two federal subpoenas related to its products, the firm discloses.